Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.

MLA

Wu, Chiao-En, et al. “Targeting Negative Regulation of P53 by MDM2 and WIP1 as a Therapeutic Strategy in Cutaneous Melanoma.” British Journal of Cancer, vol. 118, no. 4, Feb. 2018, pp. 495–508. EBSCOhost, https://doi.org/10.1038/bjc.2017.433.

APA

Wu, C.-E., Esfandiari, A., Ho, Y.-H., Wang, N., Mahdi, A. K., Aptullahoglu, E., Lovat, P., & Lunec, J. (2018). Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. British Journal of Cancer, 118(4), 495–508. https://doi.org/10.1038/bjc.2017.433

Chicago

Wu, Chiao-En, Arman Esfandiari, Yi-Hsuan Ho, Nan Wang, Ahmed Khairallah Mahdi, Erhan Aptullahoglu, Penny Lovat, and John Lunec. 2018. “Targeting Negative Regulation of P53 by MDM2 and WIP1 as a Therapeutic Strategy in Cutaneous Melanoma.” British Journal of Cancer 118 (4): 495–508. doi:10.1038/bjc.2017.433.